Camille L. Bedrosian - Nov 27, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Chief Medical Officer
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Nov 27, 2023
Transactions value $
$0
Form type
4
Date filed
11/29/2023, 04:49 PM
Previous filing
Jun 23, 2023
Next filing
Apr 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Award $0 +58.3K $0.00 58.3K Nov 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Award $0 +163K $0.00 163K Nov 27, 2023 Common Stock 163K $12.93 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 annual installments, with the first installment vesting on December 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
F2 25% of the shares subject to the option shall vest and become exercisable on December 1, 2024, with the remainder vesting in a series of 36 successive monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.